Jacobio Pharmaceuticals Group (1167) Fundamentals 2026 — Revenue Analysis | SniperIQ
Jacobio Pharmaceuticals Group (1167) is a CN-listed Healthcare company in Biotechnology with a market capitalization of HK$4.2B, trading at HK$5.35 on the HKSE. This SniperIQ fundamentals page covers Jacobio Pharmaceuticals Group's valuation, profitability (net margin -270.7%), revenue (¥52M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Jacobio Pharmaceuticals Group's market cap?
Jacobio Pharmaceuticals Group (1167) has a market capitalization of approximately HK$4.2B, trading at HK$5.35 on the HKSE. Market cap moves with the live share price.
What is Jacobio Pharmaceuticals Group's P/E ratio?
Jacobio Pharmaceuticals Group's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 4.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Jacobio Pharmaceuticals Group?
Jacobio Pharmaceuticals Group runs a net profit margin of -270.7%, a gross margin of 78.0%, and an operating margin of -317.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Jacobio Pharmaceuticals Group generate?
Jacobio Pharmaceuticals Group reported revenue of ¥52M for fiscal year 2025, with net income of -¥142M and earnings per share (EPS) of -0.18. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Jacobio Pharmaceuticals Group pay a dividend?
Jacobio Pharmaceuticals Group does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Jacobio Pharmaceuticals Group financially healthy?
Jacobio Pharmaceuticals Group carries a debt-to-equity ratio of 0.21x and a current ratio of 5.10x, with a market beta of 0.30. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Jacobio Pharmaceuticals Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Jacobio Pharmaceuticals Group (1167) the key facts are: market cap HK$4.2B, revenue ¥52M, 52-week range 3.98-11.8. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Jacobio Pharmaceuticals Group's full fundamentals live
Get Jacobio Pharmaceuticals Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.